pancreatic cancer
Conditions
Interventions
A:TAC
control group:peripheral vein
Sponsors
Department of Hepatobiliary Surgery, Xinqiao Hospital of Third Military Medical University, Chongqing
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Must have histologically (cytological) confirmed pancreatic cancer, either unresectable or metastatic; 2. Age: 18-75 years old; 3. Must have a life expectancy longer than 90 days; 4. KPS score more than 70; 5. Must at least have one measurable or evaluable tumor observation index, if within the field of radiation, radiotherapy must be discontinued for 2 months; 6. Must have completed any previous cancer surgery or radiotherapy at least 30 days before the clinical study; 7. Must not have previously received systemic chemotherapy; 8. Women in childbearing age must use appropriate birth control measures; 9. Peripheral blood picture: WBC more than 4000/ul, PLT more than 100000/ul; 10. Renal function test: Cr less than 1.3mg/dl, BUN less than 1.25*N; 11. Liver function: STB less than 2.0mg/dl, ALT less than 2.4*N, AST less than 2.5*N, AKP less than 2.5*N; 12. Must have good compliance; 13. Must give written informed consent prior to treatment.
Exclusion criteria
Exclusion criteria: 1.Patient who is participating in other pharmaceutical study; 2. Patient with other uncured cancer(s), other than pancreatic cancer; 3. Patient who has had prior chemotherapy; 4. Patient needing concomitant therapy (surgery, radiotherapy, etc.) while on study; 5. Patient with acute bacteria or virus infection; 6. Patient with severe, uncontrolled medical disease(s); 7. Patient with active brain metastasis; 8. Patient with obvious abnormal vital sign and heart, liver and renal function; 9. Patient who has a known allergy to test drug or its components; 10. Patient who is pregnant or lactating; 11. Patient with uncontrolled epilepsy and central nervous system disease(s); 12. Patient with only unmeasurable lesions such as cancerous pleural effusion, ascites, bone metastasis and meninges, etc.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Survival time;PF; | — |
Countries
China
Contacts
Public ContactHuang Xiaobing
Outcome results
None listed